{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:26:18Z","timestamp":1789010778628,"version":"build-2803163510"},"reference-count":230,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Multiple myeloma is a complex disease and immune dysfunction has been known to play an important role in the disease pathogenesis, progression, and drug resistance. Recent efforts in drug development have been focused on immunotherapies to modify the MM disease process. Here, we summarize the emerging immunotherapies in the MM treatment landscape.<\/jats:p>","DOI":"10.3390\/cells9030601","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:06:23Z","timestamp":1583240783000},"page":"601","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Immunotherapy in Multiple Myeloma"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-8872","authenticated-orcid":false,"given":"Cinnie Yentia","family":"Soekojo","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"de Mel","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, Singapore, National University Health System, 1E Kent Ridge Road, Singapore 119228, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2015-07-659490","article-title":"Myeloma escape from immunity: An \u201cinside\u201d job","volume":"126","author":"Rapoport","year":"2015","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V87.5.1928.1928","article-title":"Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells","volume":"87","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","article-title":"Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma","volume":"144","author":"Brimnes","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta 1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/86297","article-title":"A fresh look at tumor immunosurveillance and immunotherapy","volume":"2","author":"Smyth","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in Multiple Myeloma: The role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-16-0184","article-title":"New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma","volume":"22","author":"Neri","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"I107","DOI":"10.1136\/ard.58.2008.i107","article-title":"Immunomodulation by thalidomide and thalidomide analogues","volume":"58","author":"Corral","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","article-title":"CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4\u2212CD8\u2212\u03b1\u03b2TCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","author":"Feyler","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1696a","DOI":"10.1182\/blood.V112.11.1696.1696","article-title":"Regulatory T cells (Treg) are Depressed in Patients with Relapsed\/Refractory Multiple Myeloma (MM) and Increases Towards Normal Range in Responding Patients Treated with Lenalidomide (LEN)","volume":"112","author":"Quach","year":"2008","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","article-title":"Toward an understanding of nkt cell biology: Progress and paradoxes","volume":"23","author":"Kronenberg","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-1759(02)00497-0","article-title":"Detection and activation of human V\u03b124+ natural killer T cells using \u03b1-galactosyl ceramide-pulsed dendritic cells","volume":"272","author":"Fujii","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.4049\/jimmunol.163.9.4647","article-title":"Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells","volume":"163","author":"Carnaud","year":"1999","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4065\/79.7.899","article-title":"Thalidomide: Tragic Past and Promising Future","volume":"79","author":"Rajkumar","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: The National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2016.214","article-title":"The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents","volume":"52","author":"Chakraborty","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bcp.12044","article-title":"Drug-conjugated antibodies for the treatment of cancer","volume":"76","author":"Lambert","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-6-1","article-title":"A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer","volume":"6","author":"Mellor","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep34310","article-title":"CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes","volume":"6","author":"Yeap","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Jakobs","year":"2014","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI0215640","article-title":"Immune complex\u2013mediated antigen presentation induces tumor immunity","volume":"110","author":"Rafiq","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_47","first-page":"199","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"Kamps","year":"2011","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molimm.2015.01.028","article-title":"Complement in therapy and disease","volume":"67","author":"Melis","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.smim.2016.03.003","article-title":"Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies","volume":"28","author":"Taylor","year":"2016","journal-title":"Semin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2005.06.022","article-title":"Fc receptors and their interaction with complement in autoimmunity","volume":"100","author":"Schmidt","year":"2005","journal-title":"Immunol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1172\/JCI16577","article-title":"C5a anaphylatoxin is a major regulator of activating versus inhibitory Fc\u03b3Rs in immune complex\u2013induced lung disease","volume":"110","author":"Shushakova","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and Function of the ADP Ribosyl Cyclase\/CD38 Gene Family in Physiology and Pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: A (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","article-title":"CD38\/CD19: A lipid raft-dependent signaling complex in human B cells","volume":"109","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"Bakker","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_60","first-page":"4563","article-title":"Antitumor activity associated with dual targeting of CD38 and programmed death-1 pathways in preclinical models","volume":"78","author":"Bezman","year":"2018","journal-title":"Aacr Meet. Abstr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.2017.35.7_suppl.79","article-title":"CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1\/PD-L1 axis","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2018-156","article-title":"One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone","volume":"132","author":"Mateos","year":"2018","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_70","unstructured":"Luciano, J., Costa, M., Saurabh Chhabra, M., Kelly, N., Godby, M., Eva Medvedova, M., Robert, F., Cornell, M., Aric, C., and Hall, M. (2019, January 7\u201310). Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Proceedings of the 61st Annual Meeting of the American Society of Hematology, Orlando, FL, USA."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Attal, M., Richardson, P.G., Rajkumar, S.V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., and Dimopoulos, M.A. (2019). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. Lancet.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM Family Receptors and SAP Adaptors in Immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Ann. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.clml.2018.07.155","article-title":"Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide\/Dexamethasone (ELd) Versus Ld in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"18","author":"Lonial","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in reapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/01.HS9.0000564672.91201.a6","article-title":"Safety and efficacy of combination of Selinexor, Daratumumab, and Dexamethasone (SDD) in patients with multiple myeloma (MM) previously exposed to proteasome inhibitors and immunomodulatory drugs","volume":"3","author":"Gasparetto","year":"2019","journal-title":"HemaSphere"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood-2018-152","article-title":"Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)","volume":"132","author":"Yimer","year":"2018","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2018-99-111065","article-title":"Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma","volume":"132","author":"Kumar","year":"2018","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2018-151","article-title":"Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D.; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood-2018-99-114668","article-title":"Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study","volume":"132","author":"Stege","year":"2018","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/01.HS9.0000561576.58696.ae","article-title":"A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab, Pomalidomide, and Low Dose Dexamethasone vs. Pomalidomide and Low Dose Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"3","author":"Attal","year":"2019","journal-title":"HemaSphere"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.HS9.0000563836.49132.cf","article-title":"Preliminary Data: Phase 1b study of feasibility\/safety of Isatuximab short duration fixed volume infusion in combination with pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"3","author":"Usmani","year":"2019","journal-title":"HemaSphere"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2018-99-111244","article-title":"Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant","volume":"132","author":"Ocio","year":"2018","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.1200\/jco.2015.33.15_suppl.8574","article-title":"A phase I\/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM)","volume":"33","author":"Raab","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2018-153","article-title":"MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide\/Dex or Lenalidomide\/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I\/IIa, Multicenter, Dose-Escalation Study","volume":"132","author":"Raab","year":"2018","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b\u20132 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: A phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","volume":"175","author":"Mateos","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs. bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"Shpilberg","year":"2014","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1038\/bcj.2016.4","article-title":"Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: An open-label phase I trial","volume":"6","author":"Shah","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood.V120.21.4042.4042","article-title":"BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: Safety and further evidence of clinical activity","volume":"2012","author":"Heffner","year":"2012","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood.V124.21.4736.4736","article-title":"Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma: Clinical activity in patients already exposed to lenalidomide and bortezomib","volume":"124","author":"Kelly","year":"2014","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V128.22.4486.4486","article-title":"Indatuximab Ravtansine (BT062) in Combination with Low Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and\/or Refractory CD\u201356-positive Multiple Myeloma","volume":"19","author":"Ailawadhi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/jco.2011.29.15_suppl.8013","article-title":"Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed\/refractory multiple myeloma (MM)","volume":"29","author":"Berdeja","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood-2018-99-111729","article-title":"A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relpased or Refractory Multiple Myeloma","volume":"132","author":"Benson","year":"2018","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2019\/6084012","article-title":"Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets","volume":"2019","author":"Nishida","year":"2019","journal-title":"J. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_114","first-page":"1962","article-title":"Efficacy analysis from phase I study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma: A preliminary efficacy analysis","volume":"118","author":"Wolf","year":"2010","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17474086.2017.1396890","article-title":"Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia","volume":"10","author":"Ribera","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/leu.2017.219","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/jacs.5b01876","article-title":"An anti-B cell maturation antigen bispecific antibody for multiple myeloma","volume":"137","author":"Ramadoss","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38\/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release","volume":"25","author":"Fajardo","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cyto.b.21092","article-title":"CD38 and CD157: A long journey from activation markers to multifunctional molecules","volume":"84B","author":"Quarona","year":"2013","journal-title":"Cytom. Part B: Clin. Cytom."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Topp, M.S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kronke, J., Facon, T., Salnikov, A.V., and Lesley, R. (2020). Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.","DOI":"10.1200\/JCO.19.02657"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint Inhibition in Myeloma: Opportunities and Challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: A dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Mateos, M.V., Blacklock, H., Schjesvold, F., Oriol, A., Simpson, D., George, A., Goldschmidt, H., Larocca, A., Chanan-Khan, A., and Sherbenou, D. (2019). Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial. Lancet Haematol.","DOI":"10.1200\/JCO.2018.36.15_suppl.8021"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R.M., Yimer, H.A., LeBlanc, R., Takezako, N., and McCroskey, R.D. (2019). Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial. Lancet Haematol.","DOI":"10.1016\/S2352-3026(19)30109-7"},{"key":"ref_138","first-page":"1858","article-title":"Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma","volume":"130","author":"Thanendrarajan","year":"2017","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e000477","DOI":"10.1136\/esmoopen-2018-000477","article-title":"Early use of steroids affects immune cells and impairs immunotherapy efficacy","volume":"4","author":"Morgillo","year":"2019","journal-title":"Esmo Open"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","article-title":"Chimeric Antigen Receptor (CAR) therapy for multiple myeloma","volume":"172","author":"Atanackovic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nri1729","article-title":"Supernatural T cells: Genetic modification of T cells for cancer therapy","volume":"5","author":"Kershaw","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_154","unstructured":"Madduri, D., Usmani, S.Z., Jagannath, S., Singh, I., Zudaire, E., Yeh, T.-M., Allred, A.J., Banerjee, A., Goldberg, J.D., and Schecter, J.M. (2019, January 7\u201310). Results from CARTITUDE-1: A Phase 1b\/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and\/or Refractory Multiple Myeloma (R\/R MM). Proceedings of the 61st Annual Meeting of the American Society of Hematology, Orlando, FL, USA."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Garfall, A.L., Stadtmauer, E.A., Hwang, W.T., Lacey, S.F., Melenhorst, J.J., Krevvata, M., Carroll, M.P., Matsui, W.H., Wang, Q., and Dhodapkar, M.V. (2018). Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Jci Insight, 3.","DOI":"10.1172\/jci.insight.120505"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2018.36.15_suppl.8007","article-title":"bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma: Updated results from a multicenter phase I study","volume":"36","author":"Raje","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_157","first-page":"505","article-title":"Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM)","volume":"2017","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","article-title":"Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"132","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/01.HS9.0000561588.43449.88","article-title":"Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"3","author":"Li","year":"2019","journal-title":"HemaSphere"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","article-title":"Durable Remission Achieved from BCMA-Directed CAR-T Thearpy Against Relapsed or Refractory Multiple Myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed\/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1\/2 Multicenter Study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_167","first-page":"506","article-title":"Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: Initial safety and efficacy report from a clinical pilot study","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","article-title":"Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: Initial safety and efficacy report from a clinical pilot study","volume":"128","author":"Shi","year":"2018","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2018-99-113220","article-title":"Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/01.HS9.0000563764.80519.69","article-title":"B-cell maturation antigen antibody-drug conjugate (ADC), GSK2857916, in relapsed\/refractory multiple myeloma (RRMM): Final safety, efficacy and pharmacokinetic (PK) analyses from a Phase 1 study","volume":"3","author":"Popat","year":"2019","journal-title":"HemaSphere"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood.V128.22.974.974","article-title":"Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"key":"ref_173","first-page":"28","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J. Immunother."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2018-99-113118","article-title":"Safety and Efficacy of Multiantigen-Targeted T cells for Multiple Myeloma","volume":"132","author":"Lulla","year":"2018","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/mt.2011.65","article-title":"Thunder and lightning: Immunotherapy and oncolytic viruses collide","volume":"19","author":"Melcher","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Choi, A.H., O\u2019Leary, M.P., Fong, Y., and Chen, N.G. (2016). From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Biomedicines, 4.","DOI":"10.3390\/biomedicines4030018"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S136644","article-title":"Potential of oncolytic viruses in the treatment of multiple myeloma","volume":"7","author":"Bartee","year":"2017","journal-title":"Oncolytic Virother."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41408-017-0020-0","article-title":"Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma","volume":"7","author":"Meyers","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic measles virus targets high CD46 expression on multiple myeloma cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.V98.7.2002","article-title":"Systemic therapy of myeloma xenografts by an attenuated measles virus","volume":"98","author":"Peng","year":"2001","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/JVI.02134-06","article-title":"Measles virus infection of SLAM (CD150) knockin mice reproduces tropism and immunosuppression in human infection","volume":"81","author":"Ohno","year":"2007","journal-title":"J. Virol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/mt.2010.43","article-title":"Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers","volume":"18","author":"Liu","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"41275","DOI":"10.18632\/oncotarget.5753","article-title":"Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus","volume":"6","author":"Kelly","year":"2015","journal-title":"Oncotarget"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","article-title":"Reovirus as a viable therapeutic option for the treatment of multiple myeloma","volume":"18","author":"Thirukkumaran","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1038\/onc.2011.478","article-title":"Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma","volume":"31","author":"Kelly","year":"2012","journal-title":"Oncogene"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","article-title":"A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma","volume":"20","author":"Sborov","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/1535-7163.MCT-15-0240-T","article-title":"Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma","volume":"15","author":"Stiff","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bmt.2013.130","article-title":"Reovirus as a successful ex vivo purging modality for multiple myeloma","volume":"49","author":"Thirukkumaran","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/hum.2009.082","article-title":"Infection and killing of multiple myeloma by adenoviruses","volume":"21","author":"Senac","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/jvi.38.1.356-367.1981","article-title":"Inhibition of cellular DNA synthesis by vesicular stomatitis virus","volume":"38","author":"McGowan","year":"1981","journal-title":"J. Virol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/blood-2007-01-065573","article-title":"Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene","volume":"110","author":"Goel","year":"2007","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.exphem.2013.09.005","article-title":"Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo","volume":"41","author":"Yarde","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/hum.2004.15.821","article-title":"Vesicular stomatitis virus: A potential therapeutic virus for the treatment of hematologic malignancy","volume":"15","author":"Lichty","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNbeta-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omto.2017.07.001","article-title":"Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma","volume":"6","author":"Futami","year":"2017","journal-title":"Mol. Ther. Oncolyt."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"32174","DOI":"10.1038\/srep32174","article-title":"Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma","volume":"6","author":"Lei","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clml.2015.12.005","article-title":"Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells","volume":"16","author":"Bartee","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus","volume":"18","author":"Bartee","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Calton, C.M., Kelly, K.R., Anwer, F., Carew, J.S., and Nawrocki, S.T. (2018). Oncolytic Viruses for Multiple Myeloma Therapy. Cancers, 10.","DOI":"10.3390\/cancers10060198"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/nm.1776","article-title":"Engineering microRNA responsiveness to decrease virus pathogenicity","volume":"14","author":"Kelly","year":"2008","journal-title":"Nat. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Apostolopoulos, V. (2019). Cancer Vaccines: Research and Applications. Cancers, 11.","DOI":"10.3390\/cancers11081041"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/asheducation-2016.1.521","article-title":"Cellular and vaccine immunotherapy for multiple myeloma","volume":"2016","author":"Garfall","year":"2016","journal-title":"Hematology"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3389\/fimmu.2018.02265","article-title":"Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time","volume":"9","author":"Bloemendal","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with Dendritic Cell\/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J. Immunother."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1182\/blood-2011-09-382200","article-title":"Human Langerhans cells use an IL-15R-alpha\/IL-15\/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1","volume":"119","author":"Romano","year":"2012","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/blood.V126.23.4238.4238","article-title":"Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission","volume":"126","author":"Borrello","year":"2015","journal-title":"Blood"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","article-title":"The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents","volume":"131","author":"Gavriatopoulou","year":"2018","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Kaiser, M.F., Jenner, M., Cairns, D., Pawlyn, C., Paterson, A., Mottram, R., Davies, F.E., Drayson, M.T., Owen, R.G., and Morgan, G. (2019, January 7\u201310). Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches. Proceedings of the 61st Annual Meeting of the American Society of Hematology, Orlando, FL, USA.","DOI":"10.1182\/blood-2019-124819"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Li, C., Mei, H., Hu, Y., Guo, T., Liu, L., Jiang, H., Tang, L., Wu, Y., Ai, L., and Deng, J. (2019, January 7\u201310). A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed\/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial. Proceedings of the 61st Annual Meeting of the American Society of Hematology, Orlando, FL, USA.","DOI":"10.1182\/blood-2019-130340"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Costa, L.J., Wong, S.W., Berm\u00fadez, A., Rubia, J.d.l., Mateos, M.-V., Ocio, E.M., Rodr\u00edguez-Otero, P., Jesus San-Miguel, M., Li, S., and Sarmiento, R. (2019, January 7\u201310). First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Proceedings of the 61st Annual Meeting of the American Society of Hematology, Orlando, FL, USA.","DOI":"10.1182\/blood-2019-122895"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Fabry","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed\/Refractory B-Cell Non-hodgkin Lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2019-126145","article-title":"Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma","volume":"134","author":"Staehr","year":"2019","journal-title":"Blood"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"ref_225","first-page":"3473","article-title":"CAR T-cell therapy: Is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2019","journal-title":"Nat. Cancer"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Graham, C., Jozwik, A., Pepper, A., and Benjamin, R. (2018). Allogeneic CAR-T Cells: More than Ease of Access?. Cells, 7.","DOI":"10.3390\/cells7100155"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2019.224204","article-title":"Chimeric antigen receptor T-cell therapy for multiple myeloma: A consensus statement from The European Myeloma Network","volume":"104","author":"Moreau","year":"2019","journal-title":"Haematologica"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Stadtmauer, E.A., Cohen, A.D., Weber, K., Lacey, S.F., Gonzalez, V.E., Fraietta, J.J.M.A., Gabriela Plesa, M., Shea, J., Matlawski, T., and Cervini, A. (2019, January 7\u201310). First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR\/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Proceedings of the 61st Annual Meeting of the American Society of Hematology, Orlando, FL, USA.","DOI":"10.1182\/blood-2019-122374"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/3\/601\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:03:34Z","timestamp":1760173414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/3\/601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":230,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["cells9030601"],"URL":"https:\/\/doi.org\/10.3390\/cells9030601","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]}}}